Integrating Network and Pathway Information for Drug Repurposing in Diffuse Large B Cell Lymphoma
ISEF · 2026 Computational Biology and Bioinformatics
Overview
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Standard R-CHOP chemotherapy leaves many patients with relapsed or refractory disease, and salvage procedures or CAR T-cell therapies are toxic, expensive, and available only at specialized centers. Drug repurposing could provide more accessible options, but no systematic way exists to prioritize DLBCL candidates using molecular data. This project developed a computational, network- and pathway-based pipeline to repurpose existing drugs for DLBCL using public transcriptomes and drug–target databases. Bulk RNA-seq data from DLBCL cohorts were compared to GTEx spleen controls with DESeq2 to identify differentially expressed genes and dysregulated pathways. These genes were combined with curated gene–disease associations and projected onto a protein–protein interaction network, where the DIAMOnD algorithm expanded them into a DLBCL disease module. I then found that this module is significantly more connected than random gene sets, indicating a coherent disease neighborhood in the interactome. Next, I mapped 87 approved drugs to their protein targets, computed network proximity and diffusion scores to the DLBCL module, and integrated these with module targeting, expression patterns, clinical evidence, and safety to rank candidates. Known or investigational lymphoma drugs showed more favorable proximity scores than other drugs, supporting the relevance of the network metric. The final shortlist contained one approved lymphoma therapy and four non-DLBCL-approved drugs with acceptable safety profiles. This study demonstrates that a network-medicine pipeline can both rediscover existing lymphoma treatments and systematically highlight repurposing candidates for future testing in DLBCL.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2024
Small Molecule Stabilization of the CARD11 G-quadruplex Represses Transcription: Developing a Therapeutic Target for Diffuse Large B-Cell Lymphoma
ISEF · 2018
BIC Augments the Proliferative Effects of miR-155 in Diffuse Large B Cell Lymphoma Via Downregulation of Tumor Suppressor and Anti-Apoptotic Targets
ISEF · 2022
Novel-DTI: A Machine Learning Pipeline To Predict Drug-Target Interactions for Large-Scale Drug Repurposing and Drug Discovery Using Multiplex, Heterogeneous Networks
ISEF · 2025
Computational Modeling of Bispecific Antibodies Targeting CD30+ Cells in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair